DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
The article discussed results of the DECLARE-TIMI 58 study in the aspects of the previously finished trials (EMPA-REG OUTCOME and CANVAS). All three SGLT2i demonstrated the reduction of the risk of hospitalization for heart failure, as well as the risk of progression chronic kidney disease. At the s...
Saved in:
| Main Author: | Marina V. Shestakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/10289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
by: Ashot A. Avagimyan, et al.
Published: (2025-02-01) -
Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now
by: Alessandro Cuttone, et al.
Published: (2025-05-01) -
THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES
by: M. V. Shestakova, et al.
Published: (2016-05-01) -
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01) -
New opportunities for the correction of type 2 diabetes mellitus in patients with liver diseases
by: L. Yu. Morgunov, et al.
Published: (2022-01-01)